Yi-Jen Liao
Overview
Explore the profile of Yi-Jen Liao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shih M, Suk F, Chiu W, Lee C, Hsu F, Liao Y
Ecotoxicol Environ Saf
. 2024 Mar;
273:116161.
PMID: 38430581
Di(2-ethylhexyl) phthalate (DEHP) is a worldwide common plasticizer. Nevertheless, DEHP is easily leached out to the environment due to the lack of covalent bonds with plastic. High dose of DEHP...
2.
Hsu F, Yang S, Suk F, Shirakawa H, Chiu W, Liao Y
J Nutr Biochem
. 2024 Jan;
125:109565.
PMID: 38176621
Various endogenous and exogenous stimuli can result in an inflammatory response and collagen deposition in the liver, which affect liver function and increase the risk of developing liver cirrhosis and...
3.
Suk F, Hsu F, Hsu M, Chiu W, Fang C, Chen T, et al.
Life Sci
. 2023 Dec;
336:122327.
PMID: 38061536
Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, often accompanied by obesity, diabetes, and increased risks of depression and anxiety. Currently, there are no FDA-approved...
4.
Liao Y, Lee C, Twu Y, Suk F, Lai T, Chang Y, et al.
Bioengineering (Basel)
. 2023 Sep;
10(9).
PMID: 37760177
The increased proliferation and activation of hepatic stellate cells (HSCs) are associated with liver fibrosis development. To date, there are no FDA-approved drugs for the treatment of liver cirrhosis. Augmentation...
5.
Suk F, Wu C, Fang C, Chen T, Liao Y
Biomed Pharmacother
. 2023 Aug;
166:115293.
PMID: 37567069
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor. Although sorafenib and regorafenib have been approved for first-line and second-line treatment, respectively, of patients with advanced HCC, long-term treatment...
6.
Suk F, Hsu F, Lee Y, Chen T, Chiu W, Liao Y
J Nutr Biochem
. 2023 Jan;
115:109267.
PMID: 36641072
Deep-frying is a common cooking practice worldwide, and after repeated heating's, the oil undergoes various chemical reactions, including hydrolysis, polymerization, lipid oxidation, and the Maillard reaction. Studies have pointed out...
7.
Suk F, Wu C, Chiu W, Chien C, Chen T, Liao Y
Molecules
. 2022 Nov;
27(22).
PMID: 36432116
Primary liver cancer is the fifth leading death of cancers in men, and hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancer cases. Sorafenib is a first-line...
8.
Suk F, Wang Y, Chiu W, Liu C, Wu C, Chen T, et al.
Int J Mol Sci
. 2021 Aug;
22(16).
PMID: 34445279
Hepatocellular carcinoma (HCC) is the most common primary malignant tumor in the world. Sorafenib is the first-line drug for patients with advanced HCC. However, long-term treatment with sorafenib often results...
9.
Liao Y, Wang Y, Wu C, Hsu F, Chien C, Lee Y
Int J Mol Sci
. 2021 Apr;
22(6).
PMID: 33805788
Persistent chronic liver diseases increase the scar formation and extracellular matrix accumulation that further progress to liver fibrosis and cirrhosis. Nevertheless, there is no antifibrotic therapy to date. The ketogenic...
10.
Wu Y, Lu H, Lin Y, Chuang H, Su S, Liao Y, et al.
Glycobiology
. 2021 Jan;
31(5):624-635.
PMID: 33403394
Cell surface glycosylation has been known as an important modification process that can be targeted and manipulated by malignant cells to escape from host immunosurveillance. We previously showed that the...